清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B ‐CELL LYMPHOMA

作者
J.R. Westin,Luis Fayad,Y. Oki,L. Nastoupil,F. Hagemeister,Francesco Turturro,H. J. Lee,Anna Marie Rodriguez,Ken H. Young,Timothy J. McDonnell,Richard J Ford,Sattva Swarup Neelapu,R. Eric Davis
出处
期刊:Hematological Oncology [Wiley]
卷期号:35 (S2): 190-191 被引量:1
标识
DOI:10.1002/hon.2438_51
摘要

Background: Diffuse large B-cell lymphoma (DLBCL) is categorized by the cell of origin (COO) classification system into germinal center (GCB) and non-GCB subtypes. Both the immunomodulatory agent lenalidomide (L) and BTK inhibitor ibrutinib (I) have shown promising activity in the non-GCB DLBCL subtype as a single agent and in combination with chemotherapy. Preclinical studies demonstrate L + I results in synthetic lethality in non-GCB DLBCL via interferon signaling (Yang et al; Cancer Cell, 2012), but no trials have evaluated the efficacy in newly diagnosed patients. We present the first “window of opportunity” trial to use targeted therapy (rituximab, R + L + I) prior to chemotherapy in newly diagnosed DLBCL patients. Methods: In this investigator-initiated phase II trial, patients receive standard R q 21 days (d), L 25 mg po d1-10, I 560 mg po d1-21, and after two 21d RLI cycles or with progression start standard chemotherapy (initially dose adjusted EPOCH q 21d for 6 cycles, but the randomized 50303 study results prompted an amendment to allow either EPOCH or CHOP). L + I dosing may be reduced if significant toxicity criteria are met. Key eligibility criteria include histologically confirmed, treatment-naïve non-GCB DLBCL, age ≥ 18 years, and measurable disease. COO will be determined via immunohistochemistry (IHC) for eligibility and NanoString for confirmation. Patients are restaged with PET/CT (Lugano criteria, Cheson et al, JCO 2014). The primary objectives are to determine the overall response rate (ORR) after 2 cycles of RLI and complete response (CR) rate after 6 cycles of RLI + chemotherapy. Secondary objectives include safety and survival outcomes. Exploratory objectives include evaluation of baseline and therapy induced changes in gene and protein expression, mutations, and immune cell subsets in comparison with clinical outcomes. The trial will accrue 60 patients with Bayesian futility and toxicity monitoring rules. Results: At data cutoff of 3/15/17, 13 patients have enrolled, 1 withdrew consent after 1 cycle, all are available for toxicity and 11 for efficacy. The median age is 65 years, 75% are female, and the median IPI is 2 with 42% having an IPI of 3-5. All patients are non-GCB via IHC testing. Toxicities are noted for no significant rash in any patients and one case of invasive asperigillosis of the brain on a patient treated with high-dose steroids. All patients have efficacy reassessment after RLI window with an ORR of 82% and CR rate of 42%. The 6 patients who have completed all therapy have all achieved a CR. Conclusions: The combination of RLI has shown impressive efficacy both alone and with chemotherapy in this ongoing study in newly diagnosed non-GCB DLBCL. One patient had an invasive fungal infection, prompting a protocol amendment to prohibit steroid use during the window portion, and no further events have occurred. Additional results will be presented at the meeting. Keywords: diffuse large B-cell lymphoma (DLBCL); ibrutinib; lenalidomide

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青的应助被蜗牛好好飞采纳,获得10
3秒前
夏同学完成签到 ,获得积分10
4秒前
今后的应助被蜗牛好好飞采纳,获得10
9秒前
wwrjj完成签到,获得积分0
10秒前
搜集达人的应助被cc采纳,获得10
11秒前
大模型的应助被蜗牛好好飞采纳,获得10
14秒前
20秒前
20秒前
御坂10576号完成签到,获得积分10
20秒前
22秒前
义气的雅琴完成签到,获得积分10
23秒前
cc发布了新的文献求助10
25秒前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
26秒前
Harlotte完成签到 ,获得积分0
27秒前
蒋不惜完成签到,获得积分10
33秒前
changfox完成签到,获得积分10
33秒前
hyk完成签到 ,获得积分10
33秒前
milalala完成签到 ,获得积分10
43秒前
浚稚完成签到 ,获得积分10
43秒前
47秒前
冷傲的夜白完成签到,获得积分10
48秒前
岳晓燕完成签到 ,获得积分10
52秒前
52秒前
清脆代真发布了新的文献求助50
53秒前
1分钟前
谭访冬完成签到,获得积分10
1分钟前
MUAN完成签到 ,获得积分10
1分钟前
1分钟前
细腻海瑶完成签到,获得积分10
1分钟前
铁瓜李完成签到 ,获得积分10
1分钟前
1分钟前
红烧肉耶完成签到 ,获得积分10
1分钟前
小小菜完成签到 ,获得积分10
1分钟前
雪山飞龙完成签到,获得积分10
1分钟前
Agatha完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
racill完成签到 ,获得积分10
1分钟前
端庄的千凡完成签到,获得积分10
1分钟前
儒雅半双完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697